Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device(TM) in Successful Preclinical Toxicity Test
09 juin 2015 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jun 9, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ ("AC5™"), obtained data...
Arch Therapeutics Initiates Research and Development Collaboration With CURAM Centre for Research in Medical Devices
01 juin 2015 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Jun 1, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics to Present at 2015 LD MICRO Invitational Conference on June 1
18 mai 2015 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - May 18, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics' AC5(TM) Compared Favorably vs. Commercially Available Combination Hemostat in Animal Study
16 avr. 2015 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Apr 16, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Announces Favorable Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Fibrin Sealant
14 avr. 2015 07h57 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, MA--(Marketwired - Apr 14, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Cellulose-Based Hemostatic Agent
25 mars 2015 07h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Mar 25, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Arch Therapeutics Announces Positive Safety Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Toxicity Studies
23 mars 2015 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Mar 23, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in...
Pre-Clinical Animal Pilot Study Shows Arch Therapeutics' AC5(TM) Compared Favorably Versus a Popular Hemostatic Agent
23 févr. 2015 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Feb 23, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for use in bleeding during...
Nanomedicine: Nanotechnology, Biology, and Medicine Publishes Preclinical Data on Arch Therapeutics' AC5 Surgical Hemostatic Device(TM)
19 févr. 2015 08h56 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Feb 19, 2015) - Positive data from an independent third-party research group study sponsored by Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"),...
The British Standards Institution Classifies Arch Therapeutics' AC5(TM) as a Medical Device Within the European Union
17 févr. 2015 08h00 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Feb 17, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a medical device company and developer of the AC5 Surgical Hemostatic Device™...